TRICI-HF-DZHK24


Study information
TRICI-HF-DZHK24

Recruiting status

Recruiting ongoing

Recruitment start

03/2022

Patients

38

360

Clinical Trials Registration

NCT04634266

Category

Guideline relevant study

DZHK Funding

EUR 1.692.566

Operative contact
Main study center
PD Dr. med. Thomas J. Stocker
thomas.stocker@med.uni-muenchen.de

Studienzentren/Kontakt (PDF)

Tricuspid Intervention in Heart Failure (TRICI-HF-DZHK24)

An insufficient tricuspid valve is a severe and progressive disease that often leads to a progressive deterioration of the clinical condition. Until some time ago, only cardiac surgery was available to treat the valve. Only during the last few years have minimally invasive treatment methods using cardiac catheter technology become available.

The DZHK study TRICI-HF-DZHK24 is the first industry-independent, multi-centre study to examine for several such catheter-based systems whether this intervention brings benefits to patients compared to a purely drug-based therapy. For this purpose, the scientists assess how many patients survive over 12 months after the intervention and whether hospitalisation due to heart failure becomes necessary.

Publications

There are no publications aivailable yet.

Principal Investigators

Prof. Dr. med. Jörg Hausleiter
Klinikum der Universität München
PD Dr. Thomas Stocker
Ludwig-Maximilians-Universität München
Prof. Dr. Steffen Massberg
Klinikum der Universität München / Klinikum Großhadern

Press releases and news

Percutaneous tricuspid valve repair: a future route out of right heart failure? (TRICI-HF-DZHK24 study)

A new study by the German Center for Cardiovascular Research (DZHK) examines whether patients with a...

Study recruitment is available in these cities

The map only displays recruitment locations within Germany.